Current Trials Investigating the Efficacy and Safety of Vidutolimod

Checkmate Pharmaceuticals is investigating the efficacy and safety of vidutolimod in combination with checkpoint inhibitors in patients with various types and stages of cancer, including melanoma and squamous cell carcinoma of the head and neck. To learn more about vidutolimod, a virus-like particle containing a CpG-A TLR9 agonist, visit Our Science.

We are recruiting eligible participants to participate in our ongoing immuno-oncology clinical trials with vidutolimod. For more information on our trials, please view the pages below or contact us at clinicaltrials@checkmatepharma.com.

Physicians: For details on clinical trial eligibility criteria for clinical trials with vidutolimod, site locations and contacts, please visit clinicaltrials.gov. When searching for vidutolimod trials, use the product name CMP-001.

Clinical Trials Now Enrolling

Melanoma
CMP-001-010: Advanced Refractory Melanoma
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
A Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma.

CMP-001-011: First-line Melanoma
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
A Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.

Head and Neck Squamous Cell Carcinoma (HNSCC)
CMP-001-007: First-line HNSCC
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed cell death protein 1 (PD-1) blocking antibody.

Physicians: For details on clinical trial eligibility criteria for clinical trials with vidutolimod, site locations and contacts, please visit clinicaltrials.gov. When searching for vidutolimod trials, use the product name CMP-001.